Laryssa a pu présenter le modèle du Réseau de santé publique pour un vieillissement sain lors du congrès éducatif #ACG2026.
Nous avons hâte d'appliquer en Ontario les connaissances acquises.
#Gérontologie #VieillissementSain #ACG2026
Nous avons hâte d'appliquer en Ontario les connaissances acquises.
#Gérontologie #VieillissementSain #ACG2026
October 28, 2026 at 3:43 PM
Laryssa a pu présenter le modèle du Réseau de santé publique pour un vieillissement sain lors du congrès éducatif #ACG2026.
Nous avons hâte d'appliquer en Ontario les connaissances acquises.
#Gérontologie #VieillissementSain #ACG2026
Nous avons hâte d'appliquer en Ontario les connaissances acquises.
#Gérontologie #VieillissementSain #ACG2026
In the phase 3 AFFIRM trial, subcutaneous #risankizumab induction demonstrated superiority over placebo for achieving clinical remission and endoscopic response at week 12. #ACG2026
https://www.gastroenterologyadvisor.com/reports/subcutaneous-risankizumab-induction-crohn-disease/
https://www.gastroenterologyadvisor.com/reports/subcutaneous-risankizumab-induction-crohn-disease/
October 16, 2026 at 5:05 PM
In the phase 3 AFFIRM trial, subcutaneous #risankizumab induction demonstrated superiority over placebo for achieving clinical remission and endoscopic response at week 12. #ACG2026
https://www.gastroenterologyadvisor.com/reports/subcutaneous-risankizumab-induction-crohn-disease/
https://www.gastroenterologyadvisor.com/reports/subcutaneous-risankizumab-induction-crohn-disease/
In an analysis of 203 liver transplant recipients with unresectable colorectal liver metastases, overall survival was 90.9% at 1 year, 69.8% at 3 years, and 48.9% at 5 years. #ACG2026
https://www.gastroenterologyadvisor.com/reports/liver-transplant-survival-colorectal-liver-metastases/
https://www.gastroenterologyadvisor.com/reports/liver-transplant-survival-colorectal-liver-metastases/
Liver Transplantation Shows Promising Survival Outcomes in Colorectal Liver Metastases
Liver transplantation for unresectable colorectal liver metastases yielded 90.9% 1-year survival and 69.8% 3-year survival in a cohort study.
www.gastroenterologyadvisor.com
October 16, 2026 at 12:26 PM
In an analysis of 203 liver transplant recipients with unresectable colorectal liver metastases, overall survival was 90.9% at 1 year, 69.8% at 3 years, and 48.9% at 5 years. #ACG2026
https://www.gastroenterologyadvisor.com/reports/liver-transplant-survival-colorectal-liver-metastases/
https://www.gastroenterologyadvisor.com/reports/liver-transplant-survival-colorectal-liver-metastases/
Dermatology screening was low in both #IBD subtypes, with #UlcerativeColitis patients at lower rates (8.000%) compared with #Crohn disease patients (9.326%). #ACG2026
https://www.gastroenterologyadvisor.com/reports/bridging-preventive-care-gaps-key-to-managing-ulcerative-colitis-crohn-disease/
https://www.gastroenterologyadvisor.com/reports/bridging-preventive-care-gaps-key-to-managing-ulcerative-colitis-crohn-disease/
Bridging Preventive Care Gaps Key to Managing Ulcerative Colitis, Crohn Disease
A study presented at ACG reveals low dermatology and cervical cancer screening rates in patients with ulcerative colitis and Crohn disease.
www.gastroenterologyadvisor.com
October 15, 2026 at 6:02 PM
Dermatology screening was low in both #IBD subtypes, with #UlcerativeColitis patients at lower rates (8.000%) compared with #Crohn disease patients (9.326%). #ACG2026
https://www.gastroenterologyadvisor.com/reports/bridging-preventive-care-gaps-key-to-managing-ulcerative-colitis-crohn-disease/
https://www.gastroenterologyadvisor.com/reports/bridging-preventive-care-gaps-key-to-managing-ulcerative-colitis-crohn-disease/
Composite biochemical response favored #saroglitazar over placebo in US and non-US patients with primary biliary cholangitis. #ACG2026
https://www.gastroenterologyadvisor.com/reports/response-to-saroglitzar-as-second-line-treatment-for-primary-biliary-cholangitis-is-similar-in-us-other-locations/
https://www.gastroenterologyadvisor.com/reports/response-to-saroglitzar-as-second-line-treatment-for-primary-biliary-cholangitis-is-similar-in-us-other-locations/
Response to Saroglitzar as Second-Line Treatment for Primary Biliary Cholangitis is Similar in US, Other Locations
Saroglitazar shows promise as a second-line treatment for primary biliary cholangitis in US and non-US patient groups.
www.gastroenterologyadvisor.com
October 15, 2026 at 9:13 PM
Composite biochemical response favored #saroglitazar over placebo in US and non-US patients with primary biliary cholangitis. #ACG2026
https://www.gastroenterologyadvisor.com/reports/response-to-saroglitzar-as-second-line-treatment-for-primary-biliary-cholangitis-is-similar-in-us-other-locations/
https://www.gastroenterologyadvisor.com/reports/response-to-saroglitzar-as-second-line-treatment-for-primary-biliary-cholangitis-is-similar-in-us-other-locations/
Our team is presenting groundbreaking research at #ACG2026 in Nashville 🔬 Dr. Maria Abreu shared findings from a Phase II trial of a new oral medication for ulcerative colitis — plus our faculty presented advances in AI, virtual reality, #IBD therapy and more. Read the full article:
Cedars-Sinai Experts Share Research News at ACG 2026
Cedars-Sinai physicians and scientists share new research on digestive disease, including how AI and virtual reality tools may help improve patient outcomes.
www.cedars-sinai.org
October 14, 2026 at 10:50 PM
Sleep quality, but not sleep duration, is independently associated with metabolic dysfunction-associated steatotic liver disease (#MASLD) in adults #ACG2026
Read more: https://www.gastroenterologyadvisor.com/reports/sleep-disturbance-metabolic-associated-steatotic-liver-disease/
Read more: https://www.gastroenterologyadvisor.com/reports/sleep-disturbance-metabolic-associated-steatotic-liver-disease/
Sleep Disturbances Associated With MASLD Among US Adults
Poor sleep quality and daytime sleepiness are independently linked to a higher prevalence of metabolic dysfunction-associated steatotic liver disease.
www.gastroenterologyadvisor.com
October 15, 2026 at 3:04 PM
Sleep quality, but not sleep duration, is independently associated with metabolic dysfunction-associated steatotic liver disease (#MASLD) in adults #ACG2026
Read more: https://www.gastroenterologyadvisor.com/reports/sleep-disturbance-metabolic-associated-steatotic-liver-disease/
Read more: https://www.gastroenterologyadvisor.com/reports/sleep-disturbance-metabolic-associated-steatotic-liver-disease/
Use of GLP-1 RAs was associated with a lower risk for colorectal cancer among adults with obesity, but prospective trials remain necessary to establish a clear chemopreventive mechanism. #ACG2026
https://www.gastroenterologyadvisor.com/reports/glp1-ras-lower-colorectal-cancer-risk-obesity/
https://www.gastroenterologyadvisor.com/reports/glp1-ras-lower-colorectal-cancer-risk-obesity/
GLP-1 RAs Linked to Reduced Colorectal Cancer Risk in Patients With Obesity
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were associated with a significantly reduced risk for colorectal cancer in patients with obesity.
www.gastroenterologyadvisor.com
October 15, 2026 at 5:10 PM
Use of GLP-1 RAs was associated with a lower risk for colorectal cancer among adults with obesity, but prospective trials remain necessary to establish a clear chemopreventive mechanism. #ACG2026
https://www.gastroenterologyadvisor.com/reports/glp1-ras-lower-colorectal-cancer-risk-obesity/
https://www.gastroenterologyadvisor.com/reports/glp1-ras-lower-colorectal-cancer-risk-obesity/
High rate of treatment discontinuation in patients receiving GLP-1 RAs is primarily driven by gastrointestinal adverse events, suggesting that symptom management could reduce treatment discontinuation. #ACG2026
https://www.gastroenterologyadvisor.com/reports/glp1-ra-gi-side-effects-management/
https://www.gastroenterologyadvisor.com/reports/glp1-ra-gi-side-effects-management/
Managing GI Side Effects of GLP-1 RAs – Insights by Violeta Popov, MD
Early recognition and targeted management of gastrointestinal side effects can improve patient tolerance and persistence on GLP-1 RA therapy.
www.gastroenterologyadvisor.com
October 15, 2026 at 1:38 PM
High rate of treatment discontinuation in patients receiving GLP-1 RAs is primarily driven by gastrointestinal adverse events, suggesting that symptom management could reduce treatment discontinuation. #ACG2026
https://www.gastroenterologyadvisor.com/reports/glp1-ra-gi-side-effects-management/
https://www.gastroenterologyadvisor.com/reports/glp1-ra-gi-side-effects-management/
From 1999 to 2020, liver cancer mortality rates increased by 104.4% among US women, according to findings presented at #ACG2026.
Read more: https://www.gastroenterologyadvisor.com/reports/liver-cancer-mortality-rates-among-us-women-rise-sharply-over-past-two-decades/
Read more: https://www.gastroenterologyadvisor.com/reports/liver-cancer-mortality-rates-among-us-women-rise-sharply-over-past-two-decades/
Liver Cancer Mortality Rates Among US Women Rise Sharply Over Past Two Decades
Liver cancer mortality rates among US women more than doubled during the 20-year study period, between 1999 and 2020.
www.gastroenterologyadvisor.com
October 15, 2026 at 12:15 AM
From 1999 to 2020, liver cancer mortality rates increased by 104.4% among US women, according to findings presented at #ACG2026.
Read more: https://www.gastroenterologyadvisor.com/reports/liver-cancer-mortality-rates-among-us-women-rise-sharply-over-past-two-decades/
Read more: https://www.gastroenterologyadvisor.com/reports/liver-cancer-mortality-rates-among-us-women-rise-sharply-over-past-two-decades/
In #IBD patients on advanced therapy, live vaccination yields no significant rise in 30-day hospitalizations, emergency department visits, or vaccine-preventable diseases, as per data presented at #ACG2026.
https://www.gastroenterologyadvisor.com/reports/live-vaccines-safety-ibd-advanced-therapy/
https://www.gastroenterologyadvisor.com/reports/live-vaccines-safety-ibd-advanced-therapy/
Live Vaccines May Be Safe in Patients With IBD on Advanced Therapy
Live vaccines administered to patients with IBD on advanced therapy did not increase short-term hospitalizations.
www.gastroenterologyadvisor.com
October 14, 2026 at 8:20 PM
In #IBD patients on advanced therapy, live vaccination yields no significant rise in 30-day hospitalizations, emergency department visits, or vaccine-preventable diseases, as per data presented at #ACG2026.
https://www.gastroenterologyadvisor.com/reports/live-vaccines-safety-ibd-advanced-therapy/
https://www.gastroenterologyadvisor.com/reports/live-vaccines-safety-ibd-advanced-therapy/
Alcohol-associated #hepatitis has contributed to the rapid rise in alcohol-associated liver disease diagnoses since 2020, according to research results presented at #ACG2026.
https://www.gastroenterologyadvisor.com/reports/alcohol-associated-hepatitis-liver-transplant/
https://www.gastroenterologyadvisor.com/reports/alcohol-associated-hepatitis-liver-transplant/
Liver Transplant Candidates with Alcohol-Associated Hepatitis More Likely to Reach Transplant Following Clinical Improvement
Alcohol-associated hepatitis has contributed to the rapid rise in alcohol-associated liver disease diagnoses since 2020.
www.gastroenterologyadvisor.com
October 14, 2026 at 7:19 PM
Alcohol-associated #hepatitis has contributed to the rapid rise in alcohol-associated liver disease diagnoses since 2020, according to research results presented at #ACG2026.
https://www.gastroenterologyadvisor.com/reports/alcohol-associated-hepatitis-liver-transplant/
https://www.gastroenterologyadvisor.com/reports/alcohol-associated-hepatitis-liver-transplant/
A 4-week intervention with an oral #FODMAP-targeting enzyme blend yielded clinically meaningful reductions in global symptom severity across all #IBS subtypes.#ACG2026
https://www.gastroenterologyadvisor.com/reports/targeted-ibs-enzyme-supplement-improves-symptom-severity-and-patient-outcomes/
https://www.gastroenterologyadvisor.com/reports/targeted-ibs-enzyme-supplement-improves-symptom-severity-and-patient-outcomes/
Targeted IBS Enzyme Supplement Improves Symptom Severity and Patient Outcomes
Patients with irritable bowel syndrome experienced significant reductions in symptom severity after 4 weeks of using a targeted enzyme supplement.
www.gastroenterologyadvisor.com
October 14, 2026 at 1:58 PM
A 4-week intervention with an oral #FODMAP-targeting enzyme blend yielded clinically meaningful reductions in global symptom severity across all #IBS subtypes.#ACG2026
https://www.gastroenterologyadvisor.com/reports/targeted-ibs-enzyme-supplement-improves-symptom-severity-and-patient-outcomes/
https://www.gastroenterologyadvisor.com/reports/targeted-ibs-enzyme-supplement-improves-symptom-severity-and-patient-outcomes/
Adults with active eosinophilic esophagitis experienced improved esophageal distensibility plateau, and endoscopic outcomes, after treatment with dupilumab. #ACG2026
https://www.gastroenterologyadvisor.com/reports/embryo-transfer-may-become-art-of-choice-for-women-with-ibd-hoping-to-conceive/
https://www.gastroenterologyadvisor.com/reports/embryo-transfer-may-become-art-of-choice-for-women-with-ibd-hoping-to-conceive/
Embryo Transfer May Become ART of Choice for Women with IBD Hoping to Conceive
Embryo transfer yields significantly higher pregnancy rates than intrauterine insemination for women with inflammatory bowel disease.
www.gastroenterologyadvisor.com
October 13, 2026 at 7:05 PM
Adults with active eosinophilic esophagitis experienced improved esophageal distensibility plateau, and endoscopic outcomes, after treatment with dupilumab. #ACG2026
https://www.gastroenterologyadvisor.com/reports/embryo-transfer-may-become-art-of-choice-for-women-with-ibd-hoping-to-conceive/
https://www.gastroenterologyadvisor.com/reports/embryo-transfer-may-become-art-of-choice-for-women-with-ibd-hoping-to-conceive/
In 72 pediatric autoimmune liver disease patients, plasma bile acids tracked with quantitative MRCP+ measures of bile duct dilation. Routine labs did not. Cincinnati Children's poster P6273, Tue Oct 13, 10:30–4:00 CT, presented by Thuy Nguyen. #Perspectum #ACG2026
October 13, 2026 at 4:00 PM
In 72 pediatric autoimmune liver disease patients, plasma bile acids tracked with quantitative MRCP+ measures of bile duct dilation. Routine labs did not. Cincinnati Children's poster P6273, Tue Oct 13, 10:30–4:00 CT, presented by Thuy Nguyen. #Perspectum #ACG2026
In women with #IBD seeking fertility treatment, embryo transfer results in substantially higher pregnancy rates compared with intrauterine insemination. #ACG2026
https://www.gastroenterologyadvisor.com/reports/embryo-transfer-may-become-art-of-choice-for-women-with-ibd-hoping-to-conceive/
https://www.gastroenterologyadvisor.com/reports/embryo-transfer-may-become-art-of-choice-for-women-with-ibd-hoping-to-conceive/
Embryo Transfer May Become ART of Choice for Women with IBD Hoping to Conceive
Embryo transfer yields significantly higher pregnancy rates than intrauterine insemination for women with inflammatory bowel disease.
www.gastroenterologyadvisor.com
October 13, 2026 at 6:15 PM
In women with #IBD seeking fertility treatment, embryo transfer results in substantially higher pregnancy rates compared with intrauterine insemination. #ACG2026
https://www.gastroenterologyadvisor.com/reports/embryo-transfer-may-become-art-of-choice-for-women-with-ibd-hoping-to-conceive/
https://www.gastroenterologyadvisor.com/reports/embryo-transfer-may-become-art-of-choice-for-women-with-ibd-hoping-to-conceive/
Starting soon: Join us at 7:30 PM CT for "EoE on the Grand Ole Stage — Showcasing Solutions for Real-World Scenarios" live from #ACG2026: https://event.arraylive.com/app/login/4747c6f6-354d-4a49-8678-cacac6377613/H715VIRTUAL
October 12, 2026 at 9:32 PM
Starting soon: Join us at 7:30 PM CT for "EoE on the Grand Ole Stage — Showcasing Solutions for Real-World Scenarios" live from #ACG2026: https://event.arraylive.com/app/login/4747c6f6-354d-4a49-8678-cacac6377613/H715VIRTUAL
Starting soon at 8:00 PM CT >> "The New Songs on the Jukebox: TL1A Blockade and Its Emerging Role in IBD" LIVE from #ACG2026: https://event.arraylive.com/app/login/0b4ceab7-b853-43a3-a756-165ac2438310/H613VIRTUAL
October 11, 2026 at 11:01 PM
Starting soon at 8:00 PM CT >> "The New Songs on the Jukebox: TL1A Blockade and Its Emerging Role in IBD" LIVE from #ACG2026: https://event.arraylive.com/app/login/0b4ceab7-b853-43a3-a756-165ac2438310/H613VIRTUAL
We'll be at the Omni Nashville Hotel in Broadway Ballroom G-K (Floor 2) TOMORROW at 7 PM CT during #ACG2026! Experts will review current evidence related to IL-23 inhibition in IBD.
For more information, please visit >> https://events.vindicocme.com/15kYU86/5a2BUm3FtNR
For more information, please visit >> https://events.vindicocme.com/15kYU86/5a2BUm3FtNR
October 11, 2026 at 9:02 PM
We'll be at the Omni Nashville Hotel in Broadway Ballroom G-K (Floor 2) TOMORROW at 7 PM CT during #ACG2026! Experts will review current evidence related to IL-23 inhibition in IBD.
For more information, please visit >> https://events.vindicocme.com/15kYU86/5a2BUm3FtNR
For more information, please visit >> https://events.vindicocme.com/15kYU86/5a2BUm3FtNR
Join us at #ACG2026 in Nashville or virtually for expert-led discussion and a case-based game that combines collaborative challenges and friendly competition this Tuesday>> https://events.vindicocme.com/15kYU86/5a2BUm3RuSb
October 8, 2026 at 2:03 PM
Join us at #ACG2026 in Nashville or virtually for expert-led discussion and a case-based game that combines collaborative challenges and friendly competition this Tuesday>> https://events.vindicocme.com/15kYU86/5a2BUm3RuSb
Join us at #ACG2026 in Nashville or virtually for a team-based game that combines collaborative challenges and friendly competition for practical learning on Sunday >> https://events.vindicocme.com/15kYU86/5a2BUm3Rstp?utm_source=bluesky&utm_medium=Post&utm_campaign=H613
October 6, 2026 at 7:01 PM
Join us at #ACG2026 in Nashville or virtually for a team-based game that combines collaborative challenges and friendly competition for practical learning on Sunday >> https://events.vindicocme.com/15kYU86/5a2BUm3Rstp?utm_source=bluesky&utm_medium=Post&utm_campaign=H613
Encore-worthy patient care starts at #ACG2026!
Join us in Nashville or virtually via livestream to learn more: https://events.vindicocme.com/15kYU86/5a2BUm3RuSb
Join us in Nashville or virtually via livestream to learn more: https://events.vindicocme.com/15kYU86/5a2BUm3RuSb
October 5, 2026 at 6:26 PM
Encore-worthy patient care starts at #ACG2026!
Join us in Nashville or virtually via livestream to learn more: https://events.vindicocme.com/15kYU86/5a2BUm3RuSb
Join us in Nashville or virtually via livestream to learn more: https://events.vindicocme.com/15kYU86/5a2BUm3RuSb
The experts at this #ACG2026 #CE dinner symposium will discuss integrating shared decision-making and interprofessional coordination into IBD management.
Join us on Monday, 10/12 in Nashville! >> https://events.vindicocme.com/15kYU86/5a2BUm3FtNR
Join us on Monday, 10/12 in Nashville! >> https://events.vindicocme.com/15kYU86/5a2BUm3FtNR
October 4, 2026 at 1:01 PM
The experts at this #ACG2026 #CE dinner symposium will discuss integrating shared decision-making and interprofessional coordination into IBD management.
Join us on Monday, 10/12 in Nashville! >> https://events.vindicocme.com/15kYU86/5a2BUm3FtNR
Join us on Monday, 10/12 in Nashville! >> https://events.vindicocme.com/15kYU86/5a2BUm3FtNR
In-person attendees of this CE Gaming Symposium at #ACG2026 will receive an "EoE Champion" button for their participation!
Register now: https://events.vindicocme.com/15kYU86/5a2BUm3RuSb
Register now: https://events.vindicocme.com/15kYU86/5a2BUm3RuSb
October 2, 2026 at 8:26 PM
In-person attendees of this CE Gaming Symposium at #ACG2026 will receive an "EoE Champion" button for their participation!
Register now: https://events.vindicocme.com/15kYU86/5a2BUm3RuSb
Register now: https://events.vindicocme.com/15kYU86/5a2BUm3RuSb
Heading to #ACG2026 in Nashville, Oct 9–14? Thuy Nguyen, VP US Medical Affairs and Prashant Pandya, Medical Director, are there all week to talk quantitative MRI in liver disease.
October 2, 2026 at 9:59 AM
Heading to #ACG2026 in Nashville, Oct 9–14? Thuy Nguyen, VP US Medical Affairs and Prashant Pandya, Medical Director, are there all week to talk quantitative MRI in liver disease.